# EDIT — slm-full-gpu

## Metadata

ticker: EDIT
arm: slm-full-gpu
judge_prompt_version: v2
context_sha256: 84ca5337016bd7bd0e494db59b8a861e7fc0b445ace767423e7374ca3bd4d04b
slm_endpoint: slm-gpu
slm_url: http://132.145.161.150:30880
slm_served_name: qwen3.6-35b-a3b-q4km
slm_artifact: ggml-org/Qwen3.6-35B-A3B-GGUF@baec3ebee244827cda0f4557eafa8b28f7545fa6:Qwen3.6-35B-A3B-Q4_K_M.gguf sha256:671e47e0ec53c665d048b98c3ecbfd5236b5ca9c3e02ed19fc8f81f7b85140c7
slm_build: b11347-5fc4f3c8c
slm_model_path: /models/Qwen3.6-35B-A3B-Q4_K_M.gguf
slm_model_ftype: Q4_K - Medium
slm_total_slots: 4
slm_n_ctx: 32768
slm_n_params: 34660610688
slm_model_size_bytes: 20408576512
slm_thinking: off
slm_sampling: {"planner": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 1024, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.0, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "rag": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 2048, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.1, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "react": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 1024, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.0, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "section": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 768, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.1, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "synthesis": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 4096, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.2, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}}
llm_calls: 7
llm_endpoints: slm-gpu
llm_by_site: {"rag:highlights": {"calls": 1, "completion_tokens": 723, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 11.137, "latency_s_total": 11.137, "parse_failure": 0, "prompt_tokens": 2385, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "rag:risks": {"calls": 1, "completion_tokens": 466, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 8.68, "latency_s_total": 8.68, "parse_failure": 0, "prompt_tokens": 2374, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:financial_health": {"calls": 1, "completion_tokens": 134, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 4.712, "latency_s_total": 4.712, "parse_failure": 0, "prompt_tokens": 651, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:recent_developments": {"calls": 1, "completion_tokens": 170, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 5.257, "latency_s_total": 5.257, "parse_failure": 0, "prompt_tokens": 645, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:risk_factors": {"calls": 1, "completion_tokens": 198, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 5.536, "latency_s_total": 5.536, "parse_failure": 0, "prompt_tokens": 538, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:sec_filing_highlights": {"calls": 1, "completion_tokens": 145, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 4.902, "latency_s_total": 4.902, "parse_failure": 0, "prompt_tokens": 803, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "synthesis": {"calls": 1, "completion_tokens": 990, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 11.061, "latency_s_total": 11.061, "parse_failure": 0, "prompt_tokens": 1672, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}}

## Retrieved source context

STOCK DATA:
{
  "ticker": "EDIT",
  "company_name": "Editas Medicine, Inc.",
  "current_price": 2.75,
  "currency": "USD",
  "market_cap": 422345088.0,
  "forward_pe": -3.651428,
  "week_52_high": 4.537,
  "week_52_low": 1.66,
  "financial_currency": "USD",
  "revenue": 47005000.0,
  "net_income": -73949000.0,
  "profit_margin_pct": -157.32,
  "dividend_yield": 0.0,
  "sector": "Healthcare",
  "industry": "Biotechnology"
}

NEWS ARTICLES:
[
  {
    "title": null,
    "source": null,
    "published_at": null,
    "description": null
  }
]

SEC FILING SUMMARIES:
{
  "10-K": {
    "form_type": "10-K",
    "filing_date": "2026-03-09",
    "summary": "Item 1A. Risk Factors Our business is subject to numerous risks. The following important factors, among others, could cause our actual results to differ materially from those expressed in forward-looking statements made by us or on our behalf in this Annual Report on Form 10-K and other filings with the U.S. Securities and Exchange Commission (the \u201cSEC\u201d), press releases, communications with investors, and oral statements. Actual future results may differ materially from those anticipated in our forward-looking statements. We undertake no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. Risks Related to Our Financial Position and Need for Additional Capital We have incurred significant losses since inception. We expect"
  },
  "10-Q": {
    "form_type": "10-Q",
    "filing_date": "2026-08-05",
    "summary": "Item 1A. Risk Factors,\u201d as updated by our subsequent filings with the SEC. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments that we may make. You should read this Quarterly Report on Form 10-Q and the documents that we have filed as exhibits to this Quarterly Report on Form 10-Q completely and with the understanding that our actual future results may be materially di"
  }
}

RAG — SEC HIGHLIGHTS:
[From Pinecone cache] Based on the provided text from the SEC EDGAR filings for ticker EDIT, here are the key takeaways regarding the company's financial position, operational status, and risks:

**Financial Position and Capital Needs**
*   **Significant Losses:** The company has incurred substantial operating losses since inception, with net losses of $160.1 million, $237.1 million, and $153.2 million for the years ended December 31, 2025, 2024, and 2023, respectively. As of December 31, 2025, the accumulated deficit stood at $1.6 billion.
*   **Need for Additional Funding:** The company requires substantial additional capital to fund ongoing operations. If unable to raise capital when needed or on attractive terms, the company may be forced to delay, reduce, or eliminate research, product development, or commercialization efforts.
*   **Cash Runway:** Existing cash and cash equivalents as of December 31, 2025, are expected to fund operating expenses and capital expenditures into the third quarter of 2027.
*   **Limited External Sources:** The only significant committed potential external sources of funds are the right to contingent payments under collaboration agreements with BMS and retained portions of contingent upfront payments and other amounts under a license agreement with Vertex.
*   **Dilution Risks:** Raising additional capital through public or private equity offerings may cause dilution to stockholders, restrict operations, or require the relinquishment of rights to technologies or product candidates.

**Operational Status and Development**
*   **Preclinical Stage:** The company’s most advanced research programs are currently in the preclinical testing stages. It is expected to be many years, if ever, before a product candidate is ready for commercialization.
*   **Primary Candidate:** A significant portion of expenses and future activities is focused on EDIT-401, including supporting preclinical studies, preparing for clinical development, and initiating clinical trials.
*   **Increasing Expenses:** Expenses are expected to increase substantially as the company continues research and development, seeks marketing approvals, establishes manufacturing capabilities, and potentially builds sales and marketing infrastructure.

**Profitability and Commercialization Risks**
*   **No Guarantee of Profitability:** The company expects to incur losses for the foreseeable future and may never achieve or maintain profitability. Even if profitability is achieved, it may not be sustainable on a quarterly or annual basis.
*   **Commercialization Challenges:** Generating revenue will depend on successfully identifying product candidates, completing clinical trials, obtaining regulatory approval, and manufacturing and selling medicines. These activities are time-consuming, expensive, and uncertain.
*   **Revenue Timeline:** Commercial revenues are not expected for years, if at all, meaning the company must continue to rely on additional financing to achieve business objectives.

**External and Regulatory Risks**
*   **Regulatory Costs:** Expenses could exceed expectations if regulatory authorities (such as the FDA or EMA) require additional clinical or other studies.
*   **Economic and Political Factors:** Unfavorable national or global economic conditions, political unrest, or financial crises could adversely affect the business by weakening demand, disrupting supply chains, or making it difficult to raise capital on acceptable terms.
*   **Collaboration Dependencies:** The success of the business is partially dependent on collaborations, such as the one with BMS, including whether BMS exercises options to extend research programs.

RAG — RISK FACTORS:
[From Pinecone cache] The primary risk factors disclosed include:

*   **Financial Position and Need for Additional Capital:** The company has incurred significant operating losses since inception, with net losses of $160.1 million, $237.1 million, and $153.2 million for the years ended December 31, 2025, 2024, and 2023, respectively. As of December 31, 2025, the accumulated deficit was $1.6 billion. The company expects to continue incurring significant expenses and operating losses for the foreseeable future and may never achieve profitability.
*   **Need for Substantial Funding:** The company requires substantial additional funding to support ongoing activities, including the preclinical and clinical development of product candidates like EDIT-401, as well as potential commercialization expenses. If capital cannot be raised when needed, the company may be forced to delay, reduce, or eliminate research and development programs or commercialization efforts.
*   **Limited Committed External Funding:** As of December 31, 2025, the company’s existing cash and cash equivalents are expected to fund operations into the third quarter of 2027. The only significant committed potential external sources of funds are rights to contingent payments under collaboration agreements with Bristol Myers Squibb Company (BMS) and retained portions of payments under a license agreement with Vertex Pharmaceuticals.
*   **Regulatory and Development Risks:** The company’s most advanced research programs are currently in the preclinical testing stage. Expenses could increase beyond expectations if regulatory authorities require additional clinical studies. The process of identifying product candidates and conducting trials is time-consuming, expensive, and uncertain, with no guarantee of marketing approval or commercial success.
*   **Economic and Political Conditions:** Unfavorable national or global economic conditions, political unrest, or financial crises could adversely affect the business by weakening demand, disrupting supply chains, or hindering the ability to raise capital on acceptable terms.
*   **Dilution and Operational Restrictions:** Raising additional capital through equity offerings, debt financings, or other arrangements may cause dilution to stockholders, restrict operations, or require the company to relinquish rights to its technologies or product candidates.

## Pre-written sections (judge input)

### Financial Health

Editas Medicine, Inc. (EDIT) currently trades at $2.75 with a market capitalization of approximately $422.3 million. The company reported revenue of $47.0 million but faces significant profitability challenges, evidenced by a net loss of $73.9 million and a negative profit margin of -157.32%. Consequently, the forward P/E ratio is negative at -3.65, reflecting ongoing operational losses rather than earnings generation. As a pre-profit biotechnology firm, EDIT continues to rely on capital raises to fund its pipeline, presenting a high-risk financial profile for investors.

### Recent Developments

Editas Medicine, Inc. (EDIT) continues to navigate significant financial headwinds, reporting a net loss of $73.9 million and a negative profit margin of 157.32%, underscoring the company's reliance on external capital to sustain operations. The stock is currently trading near its 52-week low of $1.66 at $2.75, reflecting investor caution amid persistent losses and a lack of dividend yield. While recent SEC filings highlight ongoing risk factors related to capital needs, the absence of specific clinical or partnership news in the provided data suggests the market is pricing in near-term execution risks rather than breakthrough developments. Investors should monitor upcoming quarterly reports for updates on cash runway and pipeline progress, as the company remains in a high-risk, pre-profitability phase.

### SEC Filing Highlights
Editas Medicine reported net losses of $160.1 million for the year ended December 31, 2025, bringing the accumulated deficit to $1.6 billion as the company remains in the preclinical stage with no commercial revenue. Management estimates that existing cash and cash equivalents will fund operations through the third quarter of 2027, after which substantial additional capital will be required. The company faces significant dilution risks and relies on limited external funding sources, primarily contingent payments from collaboration agreements with BMS and Vertex. With primary expenses focused on EDIT-401, the firm expects increasing costs and does not anticipate achieving profitability in the foreseeable future.

### Risk Factors

*   **Substantial Capital Requirements and Liquidity Risk:** The company has incurred significant operating losses and an accumulated deficit of $1.6 billion, with existing cash expected to fund operations only through Q3 2027. Failure to secure additional funding could force delays or termination of R&D programs, as external capital sources are limited to contingent payments from collaborations with BMS and Vertex.
*   **Early-Stage Development and Regulatory Uncertainty:** The most advanced product candidates remain in preclinical testing, with no guarantee of regulatory approval or commercial success. The development process is highly uncertain, expensive, and time-consuming, with potential for increased costs if additional clinical studies are required.
*   **Dilution and Operational Restrictions from Financing:** Raising necessary capital through equity or debt may result in significant dilution to existing stockholders, impose restrictive covenants on operations, or require the company to relinquish rights to its technologies or product candidates.

## Audited (Exec Summary + Outlook)

### Executive Summary
Editas Medicine is a preclinical-stage biotechnology firm focused on gene editing, currently trading with a market capitalization of approximately $422.3 million while carrying an accumulated deficit of $1.6 billion. The stock is notable for its precarious liquidity position, as existing cash is projected to fund operations only through the third quarter of 2027, creating immediate pressure for external capital. The single most important near-term variable shaping the outcome is the company’s ability to secure sufficient funding or generate contingent payments from its collaborations with BMS and Vertex before its current runway expires.

### Outlook
The directional outlook for Editas Medicine is cautiously cautious, defined primarily by a binary liquidity event rather than fundamental operational momentum. The primary headwind is the imminent expiration of the current cash runway in Q3 2027, which necessitates either the successful monetization of contingent payments from BMS and Vertex or a capital raise that will likely dilute existing shareholders. Tailwinds are limited to potential positive developments in the EDIT-401 pipeline or favorable terms in new financing arrangements, but these are offset by the high probability of execution risk and regulatory uncertainty inherent in preclinical-stage gene editing therapies. Investors should monitor the trajectory of cash burn relative to the Q3 2027 deadline and the status of collaboration payments as the key variables; a delay in securing additional capital or a failure to generate expected contingent revenue would significantly weaken the investment thesis, while successful financing or partnership milestones would provide temporary stability.

---
*This brief is for informational purposes only and does not constitute financial advice.*

## Judge findings

I will now systematically evaluate every specific quantitative figure, price target, threshold, ratio, metric, percentage, named product milestone, or forward-looking number in the **Executive Summary** and **Outlook** sections.

---

### EXECUTIVE SUMMARY

---

CLAIM: "market capitalization of approximately $422.3 million"
LABEL: SUPPORTED
REASON: The raw source data lists `market_cap: 422345088.0`, which rounds to $422.3 million, and the pre-written Financial Health section states "approximately $422.3 million."

---

CLAIM: "accumulated deficit of $1.6 billion"
LABEL: SUPPORTED
REASON: The RAG SEC Highlights and Risk Factors sections both explicitly state "As of December 31, 2025, the accumulated deficit stood at $1.6 billion," and the SEC Filing Highlights pre-written section repeats this figure.

---

CLAIM: "existing cash is projected to fund operations only through the third quarter of 2027"
LABEL: SUPPORTED
REASON: The RAG SEC Highlights explicitly state "Existing cash and cash equivalents as of December 31, 2025, are expected to fund operating expenses and capital expenditures into the third quarter of 2027," confirmed in both RAG sections and the pre-written SEC Filing Highlights.

---

CLAIM: "collaborations with BMS and Vertex"
LABEL: SUPPORTED
REASON: Both RAG sections explicitly name Bristol Myers Squibb (BMS) and Vertex Pharmaceuticals as the sources of contingent payments under collaboration/license agreements.

---

### OUTLOOK

---

CLAIM: "imminent expiration of the current cash runway in Q3 2027"
LABEL: SUPPORTED
REASON: The RAG SEC Highlights and Risk Factors both state cash is expected to fund operations "into the third quarter of 2027," consistent with this characterization; the period label Q3 2027 matches the source.

---

CLAIM: "contingent payments from BMS and Vertex"
LABEL: SUPPORTED
REASON: Both RAG sections explicitly identify BMS and Vertex as the only significant committed potential external sources of contingent payments.

---

CLAIM: "EDIT-401 pipeline"
LABEL: SUPPORTED
REASON: The RAG SEC Highlights explicitly name EDIT-401 as the primary candidate with expenses focused on it, and the pre-written SEC Filing Highlights section also names EDIT-401.

---

CLAIM: "Q3 2027 deadline"
LABEL: SUPPORTED
REASON: Consistent with the source data stating cash runway extends "into the third quarter of 2027"; the period label matches.

---

*No additional quantitative figures, price targets, specific ratios, percentages, or other named metrics appear in the Executive Summary or Outlook sections beyond those evaluated above. The qualitative directional language ("cautiously cautious," "high probability," "temporary stability") contains no specific quantitative claims requiring arithmetic verification.*
